The Turkish Journal of Geriatrics (Türk Geriatri Dergisi), with ISSN 1304-2947 and E-ISSN 1307-9948, is a distinguished scholarly publication dedicated to the field of geriatrics and gerontology, proudly published by the Turkish Geriatrics Society. Established to foster knowledge and research in the aging population, this journal plays a crucial role in disseminating significant findings and advancements in the medical care of elderly individuals. Since its inception in 1998, the journal has committed to high-quality, peer-reviewed articles that explore diverse aspects of geriatric medicine, contributing vital insights to practitioners and researchers alike. Although it currently holds a Q4 ranking in the category of Geriatrics and Gerontology, the Turkish Journal of Geriatrics is on an upward trajectory, making it an essential resource for those specializing in the care of older adults. Researchers and professionals are encouraged to explore its rich archive and benefit from the open-access publishing model, promoting broader access to impactful research. For those invested in the well-being of the elderly, the Turkish Journal of Geriatrics serves not only as a platform for scholarly communication but also as a catalyst for innovation in geriatric care.

Aging Medicine, published by Wiley, is a pivotal open-access journal that has been at the forefront of research dedicated to the aging population since its inception in 2018. With a focus on both geriatric care and gerontology, the journal serves as a crucial resource for researchers, healthcare professionals, and students interested in understanding the complexities of aging and the related medical challenges. Although it holds a Q3 quartile ranking in the fields of Aging and Geriatrics and Gerontology according to the 2023 metrics, the journal continues to effectively disseminate valuable research and insights, helping to bridge gaps in knowledge and practice. With an E-ISSN of 2475-0360, it offers an open-access model that ensures broader accessibility to its published content, thus promoting collaboration and innovation across disciplines. As the journal converges towards 2024, it remains committed to evolving with the dynamics of aging research, making it a significant platform for the exchange of ideas and advancements in this essential field.

Geriatrics is a leading academic journal committed to advancing the understanding and research within the expansive field of gerontology and geriatric medicine. Published by MDPI since 2016 and featuring an Open Access model, this journal aims to disseminate high-quality research that addresses the challenges and opportunities associated with aging populations. Based in Switzerland, Geriatrics has rapidly gained recognition, achieving notable rankings in various categories such as Q2 in Gerontology and Q3 in both Aging and Geriatrics and Gerontology, making its contributions significant within the scholarly community. The journal welcomes original articles, reviews, and case studies, focusing not only on clinical aspects but also on social science perspectives related to health. Researchers and professionals in the field will find this journal a vital resource for the latest insights and trends that are crucial to improving elderly care and enhancing quality of life for aging individuals globally. With its commitment to open access, Geriatrics ensures that crucial research findings are readily available to all stakeholders, thus promoting informed dialogue and collaboration across disciplines.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, published by Wiley, stands as a leading resource in the field of geriatrics and gerontology. Established in 1953 and converging into a comprehensive academic platform through 2024, this esteemed journal is recognized for its high impact, holding a Q1 ranking in its category for 2023. It serves as a vital conduit for innovative research, clinical practices, and policy discussions aimed at improving the health and well-being of older adults. With a commitment to advancing geriatric medicine, the journal contributes significantly to the ongoing dialogue among researchers, healthcare professionals, and students dedicated to this rapidly evolving field. Although currently not offering open access options, the journal remains invaluable for those seeking to access pivotal studies and reviews that shape the future of geriatrics.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, published by SPRINGER HEIDELBERG, is an authoritative journal dedicated to advancing the field of geriatrics and gerontology. With its ISSN 0948-6704 and E-ISSN 1435-1269, this journal has been a significant source of scholarly articles since its inception in 1995, catering to researchers and practitioners amid the growing importance of ageing studies. While it currently holds a Q4 ranking in Geriatrics and Gerontology and a Q3 ranking in Gerontology and Social Sciences, its contribution spans vital topics related to health ethics and legal aspects—reflecting a comprehensive view of the challenges faced in elder care. Although it is not an open-access journal, its rigorous peer-review process ensures that the research published is of high quality and relevance. Based in Heidelberg, Germany, the journal aims to foster discourse and disseminate crucial research findings that impact the health of elderly populations, making it an essential resource for researchers, healthcare professionals, and students devoted to improving geriatric care and understanding the complexities associated with ageing.

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.